Gossamer Bio Inc. to Present at Guggenheim Securities Healthcare Innovation Conference
Gossamer Bio Inc., a late-stage clinical biopharmaceutical company, will present at the Guggenheim Securities Healthcare Innovation Conference on November 11 in Boston. The focus of the presentation will be on seralutinib, a treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. This announcement is for informational purposes only and should not be considered financial or legal advice.
Gossamer Bio Inc., a late-stage clinical biopharmaceutical company focused on developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, will present at the Guggenheim Securities Healthcare Innovation Conference on November 11 in Boston. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gossamer Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251107017321) on November 07, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
